Seizures in an Immunocompetent Adult From Treatment of Latent Tuberculosis Infection: Is Isoniazid to Blame?

Bhagyashri Navalkele, Maria X. Bueno Rios, John D. Wofford, Vijay Kumar, and Risa M. Webb

University of Mississippi Medical Center, Jackson, Mississippi, USA

Isoniazid-induced seizures are a rare adverse reaction especially in immunocompetent adults. We report a case of a healthy man with seizures shortly after ingestion of his first therapeutic dose of isoniazid with rifapentine therapy for treatment of latent tuberculosis infection. Only 6 other similar cases are reported in the literature.

Keywords. isoniazid; latent tuberculosis; pyridoxine; seizures; tuberculosis.

Latent tuberculosis infection (LTBI) is defined as *Mycobacterium tuberculosis* (TB) bacteria infecting an asymptomatic person who does not have risk of transmission to others. Worldwide, approximately 25% of the population has LTBI. According to the US National TB Surveillance System (2011–2015), an estimated 8.9 million persons (3.1%) have LTBI [1]. The Centers for Disease Control and Prevention (CDC) and American Thoracic Society strongly recommend testing and treating LTBI to avoid development of active TB disease. Treatment regimens for LTBI include isoniazid (INH), INH plus rifapentine (RPT), or rifampin (RIF) based therapy. A randomized controlled trial (RCT) published in 2011 demonstrated a once-weekly INH and RPT regimen for 12-weeks (3HP) to be as effective as 9 months of daily INH therapy for treatment of LTBI. Treatment completion rate in the directly observed once-weekly 3HP group was higher (82%) compared with the group receiving self-administered daily INH (69%) (P < .001) [2]. Increased adherence was attributed to directly observed and shorter duration of therapy. According to the recent guidelines published by the National Tuberculosis Controllers Association and CDC, INH is now considered as an alternative LTBI regimen due to long duration of therapy, hepatotoxicity, and potential low treatment completion rate [3]. Currently, the CDC recommends the 3HP regimen in persons that are 2 years or older, including those with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), as the preferred treatment of choice for LTBI [4].

Adverse effects of the 3HP regimen in the RCT indicated a higher number of cases that discontinued the 3HP regimen due to an adverse event (4.9%) compared with those on INH (3.7%) (P = .0009) [2]. However, there was no difference in serious adverse events or risk of death in either treatment group; moreover, the risk for hepatitis was lower with 3HP. A follow-up postmarketing observational study of 3288 US clinic-based patients who successfully completed the 3HP regimen reported adverse drug reaction in 35.7% of the patients [5]. The most common adverse reactions included nausea (15%), fatigue (12%), myalgias (8%), other systemic complaints (8%), and headaches (7%). Approximately 6% of patients complained of fever/chills, dizziness, or abdominal pain. Approximately 5% or less had rash/hives, appetite loss, neuropathy, diarrhea, or jaundice as reported reactions. No serious adverse reactions (including seizures) were reported. Despite the adverse reactions, 79% of the patients successfully completed LTBI treatment. Thus, the 3HP regimen is recognized as an effective, safe treatment with high treatment completion rates and potential to further decrease TB disease in the United States. In this study, we report the first case of seizures after the first dose of the 3HP regimen in an immunocompetent adult.

CASE

A 28-year-old man, originally from Pakistan, presented to the Employee Health for a pre-employment health screening. His QuantiFERON-TB Gold test was positive. Subsequent evaluation was negative for any signs or symptoms of active TB. Chest radiograph was negative for any pulmonary disease. Laboratory screening test was negative for HIV antigen/antibody with normal renal and hepatic function test. Diagnosis of LTBI was established. The patient had no other comorbidities, and he denied history of seizures. He did not have previous or active history of alcohol consumption or illicit drug use. He was not taking any medications or herbals at that time. He was initiated on the 3HP regimen (oral INH 900 mg with RPT 900 mg once weekly for 12 weeks). After ingestion of his first dose of 3HP, he returned to work. Approximately 1–2 hours postingestion, he had a medical doctor-witnessed generalized tonic-clonic (GTC) seizure lasting approximately 2 minutes. No tongue-biting,
Seizures are a rare but serious adverse reaction related to medication ingestion. Up to 6% of new-onset seizures are associated with drug toxicity [6]. Exposure to medications, including but not limited to opioids, antidepressants, antibiotics, stimulants, and immunosuppressants, can increase excitatory or reduce inhibitory neuronal activity inducing seizures. Most events are self-limited without serious consequences.

Among medications used to treat LTBI, there are currently no reports of RPT or RIF causing seizures in the adult population. The most common adverse reaction secondary to INH is elevation of serum transaminases, and the most severe and at times fatal reaction is hepatitis. Isoniazid diffuses readily across all body fluids including the cerebrospinal fluid (CSF) [7]. Isoniazid is associated with adverse reactions involving central nervous system (CNS), such as paresthesia, peripheral neuropathy, psychosis, and seizure, with undefined frequency. Usually, overdose or ingestion of a toxic dose of INH has been associated with these CNS reactions. A dose over 30 mg/kg may be associated with hallucinations, recurrent seizures, metabolic acidosis, hypotension, and coma. Death may occur at doses of over 80 mg/kg [8]. Isoniazid mainly acts by inhibiting pyridoxal-5-phosphate or pyridoxine phosphokinase enzyme, thus reducing gamma amino butyric acid (GABA) levels, an inhibitory neurotransmitter, and thus precipitating seizure activity. Pyridoxine is a cofactor in GABA synthesis and its deficiency can further enhance INH-induced seizures. Pyridoxine deficiency can be present in patients with underlying medical conditions such as pregnancy, cancer, uremia, alcoholism, chronic liver disease, and advanced age. In patients at high risk for peripheral neuropathy and other INH toxicities, concomitant supplementation of oral pyridoxine (25–50 mg daily) with INH is recommended [9]. Pyridoxine causes immediate cessation of seizures by rapidly binding to INH and restoring GABA production. The recommended pyridoxine treatment dose for an unknown INH overdose is a maximum of 5 grams intravenously to an adult or child [8]. Alternatively, in cases of the known ingested dose, a pyridoxine dose equivalent to the amount of INH ingested (gram for gram) is recommended.

In our case, the patient was immunocompetent with no known underlying risk factors to precipitate pyridoxine deficiency, and he did not consume a toxic dose of INH. Even though current literature reviews indicate that most cases of INH-induced seizures have been reported secondary to overdose or toxicity, it is worth noting that our patient received a dose 3 times higher than the usual daily dosing but consistent with intermittent dosing regimen per guidelines. He developed seizures 1–2 hours after INH and RPT ingestion. Plasma levels of INH usually peak 0.75 to 2 hours after dosing; meanwhile, CNS peak concentration occurs approximately 4 hours after ingestion [10, 11]. Peak plasma concentration of RPT occurs approximately 5 hours after ingestion, and overall CSF penetration is estimated to be low (lipophilic and plasma protein binding of 80%) [10, 12, 13]. These findings favor INH as the most likely culprit given its shorter peak time and good CSF penetration. To further determine causality, the Naranjo adverse drug reaction probability scale was applied and validated INH as probable cause for the seizures (score = 6) [14]. Due to concern for INH-induced seizures, the patient received the maximum dose of pyridoxine, which possibly prevented further seizures.

To our knowledge, only 6 case reports are published on INH-induced seizures after receiving a therapeutic INH dose (Table 1). Of the 6 reports, 67% cases were receiving INH treatment for active TB [15–18]. Of the 2 LTBI cases, 1 was an elderly patient with end-stage renal disease and 1 was an adult with HIV infection [19, 20]. All 6 reported cases had underlying medical conditions, except for 1 elderly man receiving treatment for pulmonary TB. Pyridoxine treatment was successful in achieving cessation of refractory seizures in two thirds of the reported cases. One did not respond to any treatments and died. One did not receive pyridoxine, but TB treatment was stopped.

DISCUSSION
CONCLUSIONS

Our case is unique and illustrates the possibility of risk of seizures while treating an immunocompetent adult with therapeutic doses of INH. Our patient did not have comorbidities or evidence of malnutrition. Healthcare providers should be cognizant of this uncommon but potentially severe adverse reaction and consider concomitant therapy with vitamin B6 during INH treatment and administering appropriate pyridoxine dosing if a seizure occurs.

Acknowledgments

We thank the clinicians and staff at the University of Mississippi Medical Center who supported the clinical care of this patient through expert advice and consultation.

Potential conflicts of interest. All authors: no reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

1. Haddad MB, Raz KM, Lash TL, et al. Simple estimates for local prevalence of latent tuberculosis infection, United States, 2011–2015. Emerg Infect Dis 2018; 24:1930–3.
2. Sterling TR, Villarino ME, Borisov AS, et al.; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365:2155–66.
3. Sterling TR, Njie G, Zonner D, et al. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 2020; 69:1–11.
4. Borisov AS, Bambah Morris S, Njie GI, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2018; 67:723–6.
5. Sandul AL, Nwana N, Holcombe JM, et al. High rate of treatment completion in program settings with 12-dose weekly isoniazid and rifapentine for latent mycobacterium tuberculosis infection. Clin Infect Dis 2017; 65:1085–93.
6. Chen HY, Albertson TE, Olson KR. Treatment of drug-induced seizures. Br J Clin Pharmacol 2016; 81:412–9.
7. Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb) 2010; 90:279–92.
8. Glatstein M, Carbell G, Scolnik D, et al. Pyridoxine for the treatment of isoniazid-induced seizures in intentional ingestions: the experience of a national poison center. Am J Emerg Med 2018; 36:1775–8.
9. The selection and use of essential medicines. World Health Organ Tech Rep Ser 2015; viii-xv; 1–546.
10. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169–83.
11. Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am Rev Respir Dis 1993; 148:650–5.
12. Nau R, Siergel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010; 23:858–83.
13. Jarvis B, Lamb HM. Rifapentine. Drugs 1998; 56:607–16; discussion 17.
14. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30:259–45.
15. Aesch R, Kissane J. Generalized seizures following isoniazid therapy for tuberculosis in a patient with uremia. Am J Med 1972; 53:765–74.
16. Awale AS, Patel UA, Barvaliya MI, et al. Isoniazid induced convulsions at therapeutic dose in an alcoholic and smoker patient. Curr Drug Saf 2015; 10:94–5.
17. Puri MM, Kumar L, Vishwakarma PD, Behera D. Seizures with single therapeutic dose of isoniazid. Indian J Tuberc 2012; 59:100–2.
18. Tsuobuchi K, Ikematsu Y, Hashisako M, et al. Convulsive seizures with a therapeutic dose of isoniazid. Intern Med 2014; 53:239–42.
19. Asnis DS, Bhat JG, Melchert AF. Reversible seizures and mental status changes in a dialysis patient on isoniazid preventive therapy. Ann Pharmacother 1993; 27:444–6.
20. Tajender V, Saluja J. INH induced status epilepticus: response to pyridoxine. Indian J Chest Dis Allied Sci 2006; 48:205–6.